Department of Dermatology, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand.
Department of Dermatology, School of AntiAging and Regenerative Medicine, Mae Fah Luang University, Bangkok, Thailand.
J Cosmet Dermatol. 2020 Jun;19(6):1321-1327. doi: 10.1111/jocd.13157. Epub 2019 Sep 30.
Melasma treatments have varying success and are associated with some complications.
To assess the effectiveness of platelet-rich plasma (PRP) treatment for melasma.
Ten female patients with bilateral mixed-type melasma were enrolled in our randomized, split-face, single-blinded prospective trial. Over 4 treatment sessions that each took place every 2 weeks, PRP was injected intradermally on one side of the face (PRP condition) and normal saline on the other (control condition). PRP was prepared by using the YCELLBIO Kit . Outcomes were evaluated with the modified Melasma Area and Severity Index (mMASI), Mexameter , and Antera 3D. Patient satisfaction was also assessed at baseline, at 2, 4, and 6 weeks, and 1 month after treatment completion.
mMASI score and Antera 3D-assessed melanin levels show significant improvement in the PRP condition than control condition between baseline and week 6, while patient satisfaction significantly increased over time. However, Mexameter -assessed erythema and melanin indices did not significantly differ between the control and PRP conditions, though there was a trend toward reduced pigmentation in the latter. Finally, side effects of treatment were mild and resolved spontaneously within a few days.
This is the first randomized, placebo-controlled trial study using PRP for treatment of melasma. PRP injection significantly improved melasma within 6 weeks of treatment in terms of mMASI scores, patient satisfaction, and Antera -assessed melanin levels. Hence, intradermal PRP injection could be used as an alternative or adjuvant therapy for melasma. However, additional trials are needed for more rigorous evaluation of its long-term efficacy and safety.
治疗黄褐斑的方法效果不一，并伴有一些并发症。
评估富血小板血浆（PRP）治疗黄褐斑的疗效。
我们进行了一项随机、分面、单盲前瞻性试验，纳入了 10 名双侧混合性黄褐斑女性患者。在每 2 周进行 1 次的 4 次治疗中，在面部一侧（PRP 组）皮内注射 PRP，在另一侧（对照组）皮内注射生理盐水。PRP 通过 YCELLBIO 试剂盒制备。采用改良黄褐斑面积和严重程度指数（mMASI）、Mexameter 和 Antera 3D 评估结局。在基线、2 周、4 周、6 周和治疗完成后 1 个月评估患者满意度。
与对照组相比，PRP 组在基线至第 6 周时 mMASI 评分和 Antera 3D 评估的黑色素水平显著改善，而患者满意度随时间推移显著增加。然而，Mexameter 评估的红斑和黑色素指数在对照组和 PRP 组之间没有显著差异，但后者的色素沉着有减少的趋势。最后，治疗的副作用轻微，几天内可自行消退。
这是首例使用 PRP 治疗黄褐斑的随机、安慰剂对照试验研究。PRP 注射在 6 周的治疗内可显著改善 mMASI 评分、患者满意度和 Antera 评估的黑色素水平，从而改善黄褐斑。因此，皮内 PRP 注射可作为黄褐斑的一种替代或辅助治疗方法。然而，需要更多的试验来更严格地评估其长期疗效和安全性。
